Fulcrum Therapeutics Inc (FULC)
3.305
+0.04
(+1.38%)
USD |
NASDAQ |
Nov 05, 11:39
Fulcrum Therapeutics Cash from Investing (Quarterly): -12.51M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -12.51M |
| March 31, 2024 | 38.13M |
| December 31, 2023 | 18.35M |
| September 30, 2023 | 19.02M |
| June 30, 2023 | 19.88M |
| March 31, 2023 | -93.94M |
| December 31, 2022 | -36.36M |
| September 30, 2022 | -2.279M |
| June 30, 2022 | 31.40M |
| March 31, 2022 | 19.66M |
| December 31, 2021 | -9.094M |
| September 30, 2021 | -106.64M |
| June 30, 2021 | -26.35M |
| Date | Value |
|---|---|
| March 31, 2021 | 12.42M |
| December 31, 2020 | -14.60M |
| September 30, 2020 | 14.09M |
| June 30, 2020 | -0.226M |
| March 31, 2020 | -56.40M |
| December 31, 2019 | -0.108M |
| September 30, 2019 | -0.214M |
| June 30, 2019 | -0.221M |
| March 31, 2019 | -0.401M |
| December 31, 2018 | -3.466M |
| September 30, 2018 | -0.926M |
| June 30, 2018 | -3.806M |
| March 31, 2018 | -0.783M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-106.64M
Minimum
Sep 2021
38.13M
Maximum
Mar 2024
-9.767M
Average
-0.226M
Median
Jun 2020
Cash from Investing (Quarterly) Benchmarks
| Bioventus Inc | -0.077M |
| Arcturus Therapeutics Holdings Inc | -0.328M |
| Entrada Therapeutics Inc | -24.38M |
| Johnson & Johnson | -3.128B |
| Insmed Inc | -1.003B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 58.90M |
| Cash from Financing (Quarterly) | 0.377M |
| Free Cash Flow | -12.62M |
| Free Cash Flow Per Share (Quarterly) | 0.9263 |
| Free Cash Flow to Equity (Quarterly) | 58.90M |
| Free Cash Flow Yield | -6.13% |